1
|
Ferreira PMP, Almeida AACD, Conceição MLP, Pessoa ODL, Marques LGA, Capasso R, Pessoa C. Cordia oncocalyx and oncocalyxones: From the phytochemistry to the anticancer action and therapeutic benefits against chronic diseases. Fitoterapia 2023; 169:105624. [PMID: 37500017 DOI: 10.1016/j.fitote.2023.105624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2023] [Revised: 07/23/2023] [Accepted: 07/24/2023] [Indexed: 07/29/2023]
Abstract
Cordia oncocalyx Allemão is an endemic economically underexploited plant from Brazilian semi-arid region. Herein, we carried out a well-defined bibliographic review about the pharmacological activities of oncocalyxones from C. oncocalyx and mechanisms responsible for the biomedical properties. MeSH terms were used in the scientific databases for a narrative exploration. Technological development and bioproducts were also examined. Cordia oncocalyx is a deciduous tree of sexual reproduction rich in terpenoid quinones. Among them, oncocalyxone A, a 1,4-benzoquinone, the main compound from heartwood ethanol extracts, revealed anti-inflammatory and anti-edematogenic actions induced by carrageenan and dextran and antinociceptive potential in mice provoked by acetic acid and formalin. Oncocalyxone A inhibits platelet aggregation via activation of the soluble guanylate cyclase enzyme and blocks glycation processes. In addition to the antimicrobial effects against protozoa, fungi and bacteria and relaxation of smooth muscles, oncocalyxone A reduces mean blood pressure and glycemia in diabetic rats, decreases glomerular filtration parameters and tubular transport of electrolytes, and presents in vitro antimitotic and cytotoxic action upon different types of cancers, including resistant lung carcinoma lines. It has low oral acute toxicity (LD50 > 2000 mg/kg) and activates cellular apoptosis through the production of free radicals and interactions with DNA. However, no patents were found, which also emphasizes that Brazil, as the cradle of the main articles on C. oncocalyx, is wasting time and money. Moreover, slight systemic deleterious effects in mammals stimulate the use of oncocalyxone A and related compounds as lead constituents of safer drugs against chronic diseases.
Collapse
Affiliation(s)
- Paulo Michel Pinheiro Ferreira
- Laboratory of Experimental Cancerology (LabCancer), Department of Biophysics and Physiology, Federal University of Piauí, Teresina, Brazil.
| | - Antonia Amanda Cardoso de Almeida
- Laboratory of Experimental Cancerology (LabCancer), Department of Biophysics and Physiology, Federal University of Piauí, Teresina, Brazil
| | - Micaely Lorrana Pereira Conceição
- Laboratory of Experimental Cancerology (LabCancer), Department of Biophysics and Physiology, Federal University of Piauí, Teresina, Brazil
| | | | - Lana Grasiela Alves Marques
- Postgraduate Program in Biotechnology of Natural Resources, Federal University of Ceará, Fortaleza, Brazil; Department of Physiology and Pharmacology, Federal University of Ceará, Fortaleza, Brazil
| | - Raffaele Capasso
- Department of Agricultural Sciences, University of Naples Federico II, Naples, Italy
| | - Cláudia Pessoa
- Department of Physiology and Pharmacology, Federal University of Ceará, Fortaleza, Brazil
| |
Collapse
|
2
|
Liu L, Ding W, He L, Yang Y, Guan F, Sun X, Peng Y, Chen X, Zhao W, Xiao Y, Luo P. RGD and Scutellarin Conjugate (WK001) Targeting Platelet Glycoprotein IIb/IIIa Receptor Protects from Myocardial Ischemia/Reperfusion Injury: Synthesis, Characterization, and Bioactivity Evaluation. Bioconjug Chem 2023; 34:477-488. [PMID: 36740781 DOI: 10.1021/acs.bioconjchem.2c00439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Myocardial ischemia/reperfusion (MI/R) injury is an unresolved clinical challenge. The blockade of binding fibrinogen by glycoprotein IIb/IIIa (GPIIb-IIIa) inhibitors has become a new therapeutic approach against MI/R injury. In this study, we modified the RGD structure to combine with scutellarin and synthesized a novel peptide, scutellarin-HomoArg-Gly-Asp-Trp-NH2 (WK001). Herein, reported experimental and docking evidence indicates that WK001 provides immediate and potent platelet inhibition, with stronger inhibition of platelet aggregation than eptifibatide and scutellarin. In particular, it is administered intravenously to prevent thrombus formation and attenuate myocardial fibrosis progression in vivo. Therefore, WK001 could be developed as an antiplatelet drug to treat thrombosis-associated diseases, such as stroke and myocardial infarction.
Collapse
Affiliation(s)
- Lancong Liu
- State Key Laboratories for Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau999078, China
| | - Wenfeng Ding
- Shenzhen Winkey Technology Co., Ltd., Shenzhen518000, China
| | - Lili He
- State Key Laboratories for Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau999078, China
| | - Yi Yang
- State Key Laboratories for Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau999078, China
| | - Fuyi Guan
- Shenzhen Winkey Technology Co., Ltd., Shenzhen518000, China
| | - Xinlin Sun
- Shenzhen Winkey Technology Co., Ltd., Shenzhen518000, China
| | - Yan Peng
- Shenzhen Winkey Technology Co., Ltd., Shenzhen518000, China
| | - Xue Chen
- Shenzhen Winkey Technology Co., Ltd., Shenzhen518000, China
| | - Wenhao Zhao
- Shenzhen Winkey Technology Co., Ltd., Shenzhen518000, China
| | - Yu Xiao
- Shenzhen Winkey Technology Co., Ltd., Shenzhen518000, China
| | - Pei Luo
- State Key Laboratories for Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau999078, China
| |
Collapse
|
3
|
Wan S, Cui S, Jiang M, Wu Q, Ji Y, Xu Y, Gong G. Dual-target synergistic antithrombotic mechanism of a Dabigatran etexilate analogue (HY023016). Clin Exp Pharmacol Physiol 2022; 49:567-576. [PMID: 35147244 DOI: 10.1111/1440-1681.13634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2021] [Revised: 12/26/2021] [Accepted: 01/24/2022] [Indexed: 11/30/2022]
Abstract
Thrombin has long been considered a desirable antithrombotic target, but anti-thrombin therapy without anti-platelet therapy has never achieved the ideal effect. HY023016, derived from dabigatran etexilate, exhibited a potent antithrombotic efficacy. In the present study, mechanisms underlying this effect were explored. HY023016 strongly decreased the binding of thrombin to recombinant GPIbα N-terminal sequence which was confirmed by surface plasmon resonance. Flow cytometry revealed that HY023016 selectively decreased the binding of antibody to GPIbα and inhibited the washed human platelet aggregation induced by thrombin. Fluorescence experiment showed that HY023016 remarkably inhibited exosite II by a loss of affinity for the γ'-peptide of fibrinogen. Using intravital microscopy, we observed and recorded the dynamic process of thrombus formation and found that HY023016 effectively prevented thrombus formation in rat arteriovenous shunt thrombosis model. On the basis of these findings, we propose that HY023016 provides a novel insight into the antithrombotic mechanism, which exerts synergistic anticoagulant and antiplatelet effects through thrombin and GPIbα.
Collapse
Affiliation(s)
- Sheng Wan
- Department of Pharmacology, China Pharmaceutical University, Nanjing, 211198, China
| | - Shuang Cui
- Department of Pharmacology, China Pharmaceutical University, Nanjing, 211198, China.,State Key Laboratory of Natural Medicines, Key Lab of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Tongjiaxiang 24, Nanjing, 21009, China
| | - Minrui Jiang
- Department of Pharmacology, China Pharmaceutical University, Nanjing, 211198, China
| | - Qian Wu
- Department of Pharmacology, China Pharmaceutical University, Nanjing, 211198, China
| | - Yingying Ji
- Department of Pharmacology, China Pharmaceutical University, Nanjing, 211198, China
| | - Yungen Xu
- Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, 211198, China
| | - Guoqing Gong
- Department of Pharmacology, China Pharmaceutical University, Nanjing, 211198, China
| |
Collapse
|
4
|
Starch-based magnetic nanocomposite for targeted delivery of hydrophilic bioactives as anticancer strategy. Carbohydr Polym 2021; 264:118017. [PMID: 33910740 DOI: 10.1016/j.carbpol.2021.118017] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Revised: 03/10/2021] [Accepted: 03/29/2021] [Indexed: 02/06/2023]
Abstract
Magnetic nanocomposites were synthesized for the targeted delivery of hydrophilic bioactives through guidance generated by a magnetic field. Superparamagnetic iron oxide nanoparticles (SPIONs) were used to generate hydroxyethyl starch magnetic nanocapsules (HES MNCs). This synthesis allowed the co-encapsulation of oncocalyxone A (onco A) and surface-modified magnetite nanoparticles (Fe3O4@citrate) into the same nanostructure. The synthesized nanocapsules exhibited a core-shell morphology, with an average diameter of 143 nm. This nanocomposite showed potential anticancer activity (IC50) against four human tumor cell lines: glioblastoma SNB-19 (1.010 μgmL-1), colon carcinoma HCT-116 (2.675 μgmL-1), prostate PC3 (4.868 μgmL-1), and leukemia HL-60 (2.166 μgmL-1). Additionally, in vivo toxicity and locomotor activity were evaluated in a zebrafish (Danio rerio) model. The nanocomposite exhibited in vitro cytotoxicity, prolonged drug release profile and also responded to an applied magnetic field, representing a versatile compound with perspectives for highest concentration of different hydrophilic bioactives in a target tissue through magnetic vectorization.
Collapse
|
5
|
Sbardelotto AB, Barros-Nepomuceno FWA, Soares BM, Cavalcanti BC, Ramos de Sousa RW, Costa MPD, Pessoa ODL, Pessoa C, Ferreira PMP. Cellular and biochemical antileukemic mechanisms of the meroterpenoid Oncocalyxone A. JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH. PART A 2021; 84:95-111. [PMID: 33092495 DOI: 10.1080/15287394.2020.1835763] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Oncocalyxone A, a 1,4-benzoquinone derived from Cordia oncocalyx, exhibits anti-inflammatory, antimicrobial and antidiabetic properties. The aim of this study was to (1) examine the cytotoxic actions of oncocalyxone A on human normal and tumor cell lines and (2) determine mechanistic actions underlying effects upon leukemia cells using cellular and molecular techniques. Antiproliferative studies on cancer cell lines, peripheral blood mononuclear cells, and human erythrocytes were performed using colorimetric assays. To understand cytotoxicity, assessments were performed with HL-60 leukemia cells (8, 16.5, or 33 µM) after 24 hr incubation using light and fluorescence microscopy, trypan blue, flow cytometry, Comet assay, western blot of caspases and poly-ADP-ribose polymerase (PARP), and effects on topoisomerase I and II. Oncocalyxone A exhibited cytotoxic action upon HL-60 cells and dividing leukocytes, but minimal hemolytic action on erythrocytes. Mechanistic investigations demonstrated reduction of cell viability, loss of membrane integrity, cell shrinking, chromatin condensation, blebbings, externalization of phosphatidylserine, caspase activation, PARP cleavage, mitochondrial depolarization, and DNA damage. Pre-treatment with N-acetylcysteine 4 mM significantly reduced DNA damage and prevented membrane integrity loss. Oncocalyxone A displayed free radical dependent antileukemic activity via apoptotic pathways and induced DNA damage in HL-60 cells. Oncocalyxone A possesses structural chemical simplicity enabling it to be a cost-effective alternative. These properties justify further improvements to enhance activity and selectivity and the development of pharmaceutical formulations. Abbreviations Acridine orange, AO; ANOVA, analysis of variance; BSA, bovine serum albumin; DI, Damage Index; DMSO, dimethylsulfoxide; EC50, effective concentration 50%; EDTA, ethylenediamine tetraacetic acid; EB, ethidium bromide; HCT-116, colon carcinoma line; HL-60, promyelocytic leukemia line; IC50, inhibitory concentration 50%; MTT, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; OVCAR-8, ovarian carcinoma line; NAC, N-acetylcysteine, PBMC, peripheral blood mononuclear cells; PBS, phosphate-buffered saline; PI, propidium iodide; PARP, poly-ADP-ribose polymerase; RPMI-1640, Roswell Park Memorial Institute medium; SF-295, glioblastoma line; ROS, reactive oxygen species; 7-AAD, 7-amino-actinomycin D; H2-DCF-DA, 7'-dichlorodihydrofluorescein diacetate.
Collapse
Affiliation(s)
- Aline Borba Sbardelotto
- Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará , Fortaleza, Brazil
| | | | - Bruno Marques Soares
- Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará , Fortaleza, Brazil
| | - Bruno Coêlho Cavalcanti
- Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará , Fortaleza, Brazil
| | - Rayran Walter Ramos de Sousa
- Postgraduate Program in Pharmaceutical Sciences, Federal University of Piauí , Teresina, Brazil
- Laboratory of Experimental Cancerology, Department of Biophysics and Physiology, Federal University of Piauí , Teresina, Brazil
| | - Marcília Pinheiro da Costa
- Postgraduate Program in Pharmaceutical Sciences, Federal University of Piauí , Teresina, Brazil
- Department of Pharmacy, Federal University of Piauí , Teresina, Brazil
| | | | - Cláudia Pessoa
- Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará , Fortaleza, Brazil
| | - Paulo Michel Pinheiro Ferreira
- Postgraduate Program in Pharmaceutical Sciences, Federal University of Piauí , Teresina, Brazil
- Laboratory of Experimental Cancerology, Department of Biophysics and Physiology, Federal University of Piauí , Teresina, Brazil
| |
Collapse
|
6
|
da Silva RE, Ribeiro FDOS, de Carvalho AMA, Daboit TC, Marinho-Filho JDB, Matos TS, Pessoa ODL, de Souza de Almeida Leite JR, de Araújo AR, Dos Santos Soares MJ. Antimicrobial and antibiofilm activity of the benzoquinone oncocalyxone A. Microb Pathog 2020; 149:104513. [PMID: 32950640 DOI: 10.1016/j.micpath.2020.104513] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2020] [Revised: 07/23/2020] [Accepted: 09/16/2020] [Indexed: 12/17/2022]
Abstract
Resistance to antimicrobials is a challenging issue that complicates the treatment of infections caused by bacteria and fungi, thus requiring new therapeutic options. Oncocalyxone A, a benzoquinone obtained from Auxemma oncocalyx (Allem) Taub has several biological effects; however, there is no data on its antimicrobial action. In this study, its antimicrobial and antibiofilm activities were evaluated against bacteria and fungi of clinical interest. Strains of Gram-positive and Gram-negative bacteria, and filamentous fungi and yeasts were selected to determine the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of oncocalyxone A. The antibacterial effect of oncocalyxone A was studied using survival curves, atomic force microscopy (AFM), and the involvement of oxidative stress. We examined the inhibitory action of the molecule on biofilm formation and its hemolytic activity against human erythrocytes. Our results showed that among the strains tested, Staphylococcus epidermidis was highly sensitive to the action of oncocalyxone A, with an MIC of 9.43 μg/mL. In most bacterial strains analyzed, a bacteriostatic effect was observed, though the molecule showed no antifungal activity. Antibiofilm activity was observed against the methicillin-resistant S. aureus bacteria. Additionally, results from atomic force microscopy imaging showed that oncocalyxone A significantly altered bacterial morphology. Further, oncocalyxone A showed no hemolytic activity at concentrations ≥151 μg/mL. Together, our results demonstrate the antibacterial and antibiofilm potential of oncocalyxone A, indicating its therapeutic potential against bacterial resistance.
Collapse
Affiliation(s)
- Raí Emanuel da Silva
- Center of Research in Medicinal Plants - NPPM, Federal University of Piauí - UFPI, Teresina, Piauí, Brazil
| | - Fábio de Oliveira Silva Ribeiro
- Biotechnology and Biodiversity Center Research - BIOTEC, Federal University of Delta do Parnaíba - UFDPar, Parnaíba, Piauí, Brazil; Center for Research in Applied Morphology and Immunology, NuPMIA, University of Brasilia, Brasilia, Brazil
| | - Andressa Maria A de Carvalho
- Group of Advanced Studies in Medical Mycology - GEAMICOL, Federal University of Delta do Parnaíba - UFDPar, Parnaíba, Piauí, Brazil
| | - Tatiane Caroline Daboit
- Group of Advanced Studies in Medical Mycology - GEAMICOL, Federal University of Delta do Parnaíba - UFDPar, Parnaíba, Piauí, Brazil
| | | | - Taynara Simão Matos
- Department of Organic and Inorganic Chemistry, Federal University of Ceará - UFC, Fortaleza, Ceará, Brazil
| | | | - José Roberto de Souza de Almeida Leite
- Biotechnology and Biodiversity Center Research - BIOTEC, Federal University of Delta do Parnaíba - UFDPar, Parnaíba, Piauí, Brazil; Center for Research in Applied Morphology and Immunology, NuPMIA, University of Brasilia, Brasilia, Brazil
| | - Alyne Rodrigues de Araújo
- Biotechnology and Biodiversity Center Research - BIOTEC, Federal University of Delta do Parnaíba - UFDPar, Parnaíba, Piauí, Brazil.
| | | |
Collapse
|
7
|
Validation of an HPLC–UV Method for Quantifying Oncocalyxone A in Different Media and Nanocapsules. Chromatographia 2019. [DOI: 10.1007/s10337-019-03716-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
8
|
Xavier-Júnior F, Tavares C, Rabello M, Hernandes M, Bezerra B, Ayala A, Pessoa O, Ximenes R, Santos-Magalhães N. Elucidation of the mechanism of complexation between oncocalyxone A and cyclodextrins by isothermal titration calorimetry and molecular modeling. J Mol Liq 2019. [DOI: 10.1016/j.molliq.2018.10.129] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
9
|
de Melo ISV, dos Santos AF, de Lemos TLG, Goulart MOF, Santana AEG. Oncocalyxone A functions as an anti-glycation agent in vitro. PLoS One 2015; 10:e0131222. [PMID: 26110531 PMCID: PMC4482150 DOI: 10.1371/journal.pone.0131222] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2015] [Accepted: 05/29/2015] [Indexed: 12/26/2022] Open
Abstract
Advanced glycation endproducts (AGE) are the result of post-translational changes to proteins, which ultimately compromise their structure and/or function. The identification of methods to prevent the formation of these compounds holds great promise in the development of alternative therapies for diseases such as diabetes. Plants used in traditional medicine are often rich sources of anti-glycation agents. Therefore, in this study, we investigated the anti-glycation activity of one such compound, Oncocalyxone A (Onco A). Using spectrofluorimetric techniques, we determined that Onco A inhibits AGE formation in a concentration-dependent manner. Its IC50 value (87.88 ± 3.08 μM) was almost two times lower than the standard anti-glycation compound aminoguanidine (184.68 ± 4.85 μM). The excellent anti-glycation activity of Onco A makes it an exciting candidate for the treatment of diseases associated with excessive accumulation of AGE. However, additional studies are necessary to identify its mechanism of action, as well as the in vivo response in suitable model organisms.
Collapse
Affiliation(s)
- Ingrid Sofia Vieira de Melo
- Instituto de Química e Biotecnologia, Universidade Federal de Alagoas. Endereço: Cidade universitária, BR 101 (km 14), Tabuleiro dos Martins, CEP, 57072–970, Maceió, AL, Brasil
- Departamento de agroindústria, Instituto Federal de Alagoas. Endereço: Conjunto Residencial Astolfo Lopes, s/n—Cidade Alta, CEP, 57820–000, Murici, AL, Brasil
| | - Aldenir Feitosa dos Santos
- Departamento de Química, Universidade Estadual de Alagoas. Endereço: Av. Governador Luís Cavalcante, Alto do Cruzeiro, CEP, 57312–270, Arapiraca, AL, Brasil
| | - Telma Leda Gomes de Lemos
- Departamento de Química Orgânica e Inorgânica, Universidade Federal do Ceará. Endereço: Av. Mister Hull, Campus do Pici, CEP, 60451–970, Fortaleza, CE, Brasil
| | - Marília Oliveira Fonseca Goulart
- Instituto de Química e Biotecnologia, Universidade Federal de Alagoas. Endereço: Cidade universitária, BR 101 (km 14), Tabuleiro dos Martins, CEP, 57072–970, Maceió, AL, Brasil
| | - Antônio Euzébio Goulart Santana
- Instituto de Química e Biotecnologia, Universidade Federal de Alagoas. Endereço: Cidade universitária, BR 101 (km 14), Tabuleiro dos Martins, CEP, 57072–970, Maceió, AL, Brasil
- * E-mail:
| |
Collapse
|
10
|
Sayonara DMV, Maria ADF, Priscila VG, Glauce SBV, Maria JT. In vitro and in vivo evaluation of quinones from Auxemma oncocalyx Taub. on Leishmania braziliensis. ACTA ACUST UNITED AC 2015. [DOI: 10.5897/jmpr2014.5141] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
11
|
Barreto ACH, Santiago VR, Freire RM, Mazzetto SE, Denardin JC, Mele G, Cavalcante IM, Ribeiro MENP, Ricardo NMPS, Gonçalves T, Carbone L, Lemos TLG, Pessoa ODL, Fechine PBA. Magnetic nanosystem for cancer therapy using oncocalyxone a, an antitomour secondary metabolite isolated from a Brazilian plant. Int J Mol Sci 2013; 14:18269-83. [PMID: 24013376 PMCID: PMC3794780 DOI: 10.3390/ijms140918269] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2013] [Revised: 06/23/2013] [Accepted: 07/13/2013] [Indexed: 11/17/2022] Open
Abstract
This paper describes the investigation and development of a novel magnetic drug delivery nanosystem (labeled as MO-20) for cancer therapy. The drug employed was oncocalyxone A (onco A), which was isolated from Auxemma oncocalyx, an endemic Brazilian plant. It has a series of pharmacological properties: antioxidant, cytotoxic, analgesic, anti-inflammatory, antitumor and antiplatelet. Onco A was associated with magnetite nanoparticles in order to obtain magnetic properties. The components of MO-20 were characterized by XRD, FTIR, TGA, TEM and Magnetization curves. The MO-20 presented a size of about 30 nm and globular morphology. In addition, drug releasing experiments were performed, where it was observed the presence of the anomalous transport. The results found in this work showed the potential of onco A for future applications of the MO-20 as a new magnetic drug release nanosystem for cancer treatment.
Collapse
Affiliation(s)
- Antônio C. H. Barreto
- Advanced Materials Chemistry Group (GQMAT), Analytical and Physical-Chemistry Department, Federal University of Ceará (UFC), Campus do Pici 12100, CEP 60451-970 Fortaleza-CE, Brazil; E-Mails: (A.C.H.B.); (V.R.S.); (R.M.F.)
- Products Laboratory and Process Technology (LPT), Department of Organic and Inorganic Chemistry, Federal University of Ceará, Fortaleza-CE 12100, Brazil; E-Mail:
| | - Vivian R. Santiago
- Advanced Materials Chemistry Group (GQMAT), Analytical and Physical-Chemistry Department, Federal University of Ceará (UFC), Campus do Pici 12100, CEP 60451-970 Fortaleza-CE, Brazil; E-Mails: (A.C.H.B.); (V.R.S.); (R.M.F.)
- Products Laboratory and Process Technology (LPT), Department of Organic and Inorganic Chemistry, Federal University of Ceará, Fortaleza-CE 12100, Brazil; E-Mail:
| | - Rafael M. Freire
- Advanced Materials Chemistry Group (GQMAT), Analytical and Physical-Chemistry Department, Federal University of Ceará (UFC), Campus do Pici 12100, CEP 60451-970 Fortaleza-CE, Brazil; E-Mails: (A.C.H.B.); (V.R.S.); (R.M.F.)
| | - Selma E. Mazzetto
- Products Laboratory and Process Technology (LPT), Department of Organic and Inorganic Chemistry, Federal University of Ceará, Fortaleza-CE 12100, Brazil; E-Mail:
| | - Juliano C. Denardin
- Physical Department, Santiago University of Chile (USACH), Av. Ecuador 3493, Santiago 9160000, Chile; E-Mail:
| | - Giuseppe Mele
- Department of Engineering for Innovation, University of Salento, Via Arnesano, Lecce 73100, Italy; E-Mail:
| | - Igor M. Cavalcante
- Laboratory of Polymers and Materials Innovation (LPIM), Department of Organic and Inorganic Chemistry, Federal University of Ceará, Ceará 12100, Brazil; E-Mails: (I.M.C.); (M.E.N.P.R.); (N.M.P.S.R.); (T.L.G.L.); (O.D.L.P)
| | - Maria E. N. P. Ribeiro
- Laboratory of Polymers and Materials Innovation (LPIM), Department of Organic and Inorganic Chemistry, Federal University of Ceará, Ceará 12100, Brazil; E-Mails: (I.M.C.); (M.E.N.P.R.); (N.M.P.S.R.); (T.L.G.L.); (O.D.L.P)
| | - Nágila M. P. S. Ricardo
- Laboratory of Polymers and Materials Innovation (LPIM), Department of Organic and Inorganic Chemistry, Federal University of Ceará, Ceará 12100, Brazil; E-Mails: (I.M.C.); (M.E.N.P.R.); (N.M.P.S.R.); (T.L.G.L.); (O.D.L.P)
| | - Tamara Gonçalves
- Department of Pharmacy, Federal University of Ceará (UFC), Fortaleza-Ceará 12100, Brazil; E-Mail:
| | - Luigi Carbone
- National Nanotechnology Laboratory, Nanoscience Institute-CNR Via Arnesano, Lecce 73100, Italy; E-Mail:
| | - Telma L. G. Lemos
- Laboratory of Polymers and Materials Innovation (LPIM), Department of Organic and Inorganic Chemistry, Federal University of Ceará, Ceará 12100, Brazil; E-Mails: (I.M.C.); (M.E.N.P.R.); (N.M.P.S.R.); (T.L.G.L.); (O.D.L.P)
| | - Otília D. L. Pessoa
- Laboratory of Polymers and Materials Innovation (LPIM), Department of Organic and Inorganic Chemistry, Federal University of Ceará, Ceará 12100, Brazil; E-Mails: (I.M.C.); (M.E.N.P.R.); (N.M.P.S.R.); (T.L.G.L.); (O.D.L.P)
| | - Pierre B. A. Fechine
- Advanced Materials Chemistry Group (GQMAT), Analytical and Physical-Chemistry Department, Federal University of Ceará (UFC), Campus do Pici 12100, CEP 60451-970 Fortaleza-CE, Brazil; E-Mails: (A.C.H.B.); (V.R.S.); (R.M.F.)
| |
Collapse
|
12
|
Joshi BD, Srivastava A, Honorato SB, Tandon P, Pessoa ODL, Fechine PBA, Ayala AP. Study of molecular structure, vibrational, electronic and NMR spectra of oncocalyxone A using DFT and quantum chemical calculations. SPECTROCHIMICA ACTA. PART A, MOLECULAR AND BIOMOLECULAR SPECTROSCOPY 2013; 113:367-377. [PMID: 23747376 DOI: 10.1016/j.saa.2013.05.018] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/29/2012] [Revised: 05/07/2013] [Accepted: 05/08/2013] [Indexed: 06/02/2023]
Abstract
Oncocalyxone A (C17H18O5) is the major secondary metabolite isolated from ethanol extract from the heartwood of Auxemma oncocalyx Taub popularly known as "pau branco". Oncocalyxone A (Onco A) has many pharmaceutical uses such as: antitumor, analgesic, antioxidant and causative of inhibition of platelet activation. We have performed the optimized geometry, total energy, conformational study, molecular electrostatic potential mapping, frontier orbital energy gap and vibrational frequencies of Onco A employing ab initio Hartree-Fock (HF) and density functional theory (DFT/B3LYP) method with 6-311++G(d,p) basis set. Stability of the molecule arising from hyperconjugative interactions and/or charge delocalization has been analyzed using natural bond orbital (NBO) analysis. UV-vis spectrum of the compound was recorded in DMSO and MeOH solvent. The TD-DFT calculations have been performed to explore the influence of electronic absorption spectra in the gas phase, as well as in solution environment using IEF-PCM and 6-31G basis set. The (13)C NMR chemical shifts have been calculated with the B3LYP/6-311++G(d,p) basis set and compared with the experimental values. These methods have been used as tools for structural characterization of Onco A.
Collapse
|
13
|
Gupta AK, Verma AK, Kailashiya J, Singh SK, Kumar N. Sitagliptin: anti-platelet effect in diabetes and healthy volunteers. Platelets 2012; 23:565-70. [PMID: 22950787 DOI: 10.3109/09537104.2012.721907] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Sitagliptin, a selective dipeptidyl peptidase-4 inhibitor drug is used to treat type-2 diabetes (T2DM). We investigated the anti-platelet activity of sitagliptin in patients with T2DM and in in vitro samples obtained from healthy humans. Patients with T2DM (27 male + 23 female) were selected and followed up before (control) and after treatment with sitagliptin for up to 3 months. Platelets were isolated from the blood of sitagliptin treated patients and controls. Patients with T2DM treated with sitagliptin for 1and 3 months, showed 10 ± 2% and 30 ± 5% inhibition of platelet aggregation, respectively. For the in vitro study, platelets from 10 normal humans (n = 10) were isolated. Platelet aggregation, intracellular free calcium and tyrosine phosphorylation of multiple proteins were measured by aggregometer, spectrofluorometer and western blotting, respectively. Platelets pre-treated with 5 and 10 µg/ml of sitagliptin, showed 25 ± 4% and 40 ± 6% inhibition of thrombin-induced platelet aggregation, respectively. Sitagliptin decreased intracellular free calcium (2.5-fold) and tyrosine phosphorylation of multiple proteins in thrombin-induced platelet activation. Sitagliptin inhibited platelet aggregation in T2DM as well as in healthy humans. Sitagliptin has significant concentration-dependent anti-platelet activity. This activity was due to its inhibitory effect on intracellular free calcium and tyrosine phosphorylation.
Collapse
Affiliation(s)
- Ashish Kumar Gupta
- Department of Biochemistry, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
| | | | | | | | | |
Collapse
|
14
|
Kobsar A, Koessler J, Kehrer L, Gambaryan S, Walter U. The thrombin inhibitors hirudin and Refludan(®) activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets. Thromb Haemost 2012; 107:521-9. [PMID: 22234363 DOI: 10.1160/th11-07-0461] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2011] [Accepted: 12/01/2011] [Indexed: 11/05/2022]
Abstract
A number of direct thrombin inhibitors are successfully used clinically and experimentally as novel antithrombotics and specific anticoagulants. They are also used as anticoagulants in certain blood collection tubes for the analysis of platelet function. A series of platelet function tests have emerged to measure adequate responses to antiplatelet therapy. For comparative and practical reasons, it would be of advantage to use the same anticoagulant in blood collection tubes for different methods, e.g. thrombin inhibitors. However, there are little data on the effects of thrombin inhibitors on platelet signalling pathways that could influence results. We examined the applicability of thrombin inhibitor containing blood for platelet reactivity index (PRI) measurements of the VASP assay and investigated the effects of two thrombin inhibitors (hirudin and lepirudin) on cAMP- and cGMP-mediated signalling pathways in washed human platelets. We show that induction of VASP phosphorylation by PGE1 is markedly reduced in lepirudin containing blood samples. In consequence, PRI levels were highly variable compared to routinely used citrated blood. Surprisingly, in vitro incubation of platelets with thrombin inhibitors increases platelet cGMP levels and induces NOS independent sGC/PKG-mediated VASP phosphorylation. We conclude that thrombin inhibitors activate sGC/PKG-dependent pathways resulting in an increase of VASP phosphorylation which contributes to deviations in PRI measurements. These effects of thrombin inhibitors on sGC- and cGMP-mediated pathways including increased VASP phosphorylation may indicate the presence of an important additional platelet-based mechanism for the reduction of thrombus formation and thromboembolism by thrombin inhibitors.
Collapse
Affiliation(s)
- Anna Kobsar
- Institut fuer Klinische Biochemie und Pathobiochemie-Zentrallabor, Universitaetsklinikum Wuerzburg, Wuerzburg, Germany.
| | | | | | | | | |
Collapse
|